A prospective study of steroid maintenance therapy in angioimmunoblastic T cell lymphoma

A prospective study of steroid maintenance therapy in angioimmunoblastic T cell lymphoma - Steroid maintenance therapy in AITL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010338

Enrollment

Registered

2013-03-29

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioimmunoblastic T cell lymphoma

Interventions

Following 1st course of CHOP therapy, PSL 0.5mg/kg/day was initiated from day 6 as maintenance therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients previously untreated for AITL

Exclusion criteria

Exclusion criteria: Patients with active malignancy other than lymphoma Patients positive for HBs-Ag, HCV-Ab, HIV-Ab, HTLV-1-Ab Patients with active tuberculosis infection Patients that require antibiotecs therapy for infection

Design outcomes

Primary

Measure	Time frame
2-year overall survival	—

Secondary

Measure	Time frame
1-year overall survival 1-year event-free survival 2-year event-free survival Overall response rate Time to treatment failure Cumulative incidence of infection	—

Countries

Japan

Contacts

Public ContactMasatoshi Sakurai

Keio University of Medicine Division of Hematology

sakurai821019@aol.com03-5363-3785

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026